The cash price of the popular weight-loss drug Wegovy was lowered by 30% on Monday, now priced at $349, down from $499.

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

The new pricing strategy aims to attract Americans willing to purchase medications directly from Novo Nordisk, bypassing insurance.

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market ...

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.